Invitrogen™ Belimumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Product Code	Brand	Quantity
30282839	Invitrogen™ MA558447	100 μg
30284670	Invitrogen™ MA558448	1 mg

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Belimumab is an intravenous immunosuppressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1lambda monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.

Specifications

• Antigen: Belimumab
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Classification: Recombinant Monoclonal
• Form: Lyophilized
• Isotype: IgG1
• Target Species: Human
• Gene Alias: hBlySmAb-1.1; LymphoStat-B
• Product Type: Antibody

• Concentration: 1 mg/mL
• Applications: ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
• Conjugate: Unconjugated
• Host Species: Human
• Regulatory Status: RUO
• Formulation: 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
• Primary or Secondary: Primary
• Purification Method: Protein A